Details

Autor(en) / Beteiligte

• Verheijen, Marcha
• Sarkans, Ugis
• Wolski, Witold
• Jennen, Danyel
• Caiment, Florian
• Kleinjans, Jos
• Agarkova, Irina
• Atkinson, Francis L.
• Bachmann, Ivo
• Baier, Vanessa
• Barel, Gal
• Bauer, Chris
• van den Beucken, Twan
• Boerno, Stefan
• Bosc, Nicolas
• Carey, Conn
• Castell, José V.
• Clayton, Olivia
• Cordes, Henrik
• Deeb, Sally
• Gmuender, Hans
• Gotta, Stefano
• Guye, Patrick
• Hersey, Anne
• Herwig, Ralf
• Heymans, Stephane
• Hunt, Peter
• Hunter, Fiona M. I.
• Hynes, James
• Keun, Hector
• Kouloura, Eirini
• Kuepfer, Lars
• Kunz, Laura
• Lewalle, Alex
• Lienhard, Matthias
• Martínez-Sena, Teresa
• Merken, Jort
• Minguet, Jasmine
• Nguyen, Nhan
• Niederer, Steven
• Nudischer, Ramona
• Asensio, Juan Ochoteco
• Oliveira, Bernardo
• Panse, Christian
• Pluess, Carla
• Roth, Adrian B.
• Schlapbach, Ralph
• Schrooders, Yannick
• Schuchhardt, Johannes
• Segall, Matthew
• Selevsek, Nathalie
• Sepulveda, Pilar
• Smit, Ines
• Thiel, Christoph
• Timmermann, Bernd
• Wittenberger, Timo
• Zerck, Alexandra

Titel

Multi-omics HeCaToS dataset of repeated dose toxicity for cardiotoxic & hepatotoxic compounds

Ist Teil von

• Scientific data, 2022-11, Vol.9 (1), p.699-699, Article 699

Ort / Verlag

London: Nature Publishing Group

Erscheinungsjahr

2022

Quelle

EZB Electronic Journals Library

Beschreibungen/Notizen

• Abstract The data currently described was generated within the EU/FP7 HeCaToS project ( He patic and Ca rdiac To xicity S ystems modeling). The project aimed to develop an in silico prediction system to contribute to drug safety assessment for humans. For this purpose, multi-omics data of repeated dose toxicity were obtained for 10 hepatotoxic and 10 cardiotoxic compounds. Most data were gained from in vitro experiments in which 3D microtissues (either hepatic or cardiac) were exposed to a therapeutic (physiologically relevant concentrations calculated through PBPK-modeling) or a toxic dosing profile (IC20 after 7 days). Exposures lasted for 14 days and samples were obtained at 7 time points (therapeutic doses: 2-8-24-72-168-240-336 h; toxic doses 0-2-8-24-72-168-240 h). Transcriptomics (RNA sequencing & microRNA sequencing), proteomics (LC-MS), epigenomics (MeDIP sequencing) and metabolomics (LC-MS & NMR) data were obtained from these samples. Furthermore, functional endpoints (ATP content, Caspase3/7 and O2 consumption) were measured in exposed microtissues. Additionally, multi-omics data from human biopsies from patients are available. This data is now being released to the scientific community through the BioStudies data repository ( https://www.ebi.ac.uk/biostudies/ ).